The mainstay of treatment is surgical excision. Two adjuvant therapeutic strategies are Stereotactic surgery (SRS) and fractionated convention radiotherapy (FCRT). Both are highly effective means of treatment. Surgery Surgical excision of the<unk>  is the primary consensus among practicing physicians. The surgeons perform a craniotomy to remove the tumor. The ability to remove the tumor and to what extent it is removed is dependent upon the location of the tumor and surgeon experience and preference. The extent of the disease plays a large part in determining how effective the surgery will be. The main goal of a complete surgical resection, of the tumor, can also be hindered by the adherence of the tumor to adjoining structures or hemorrhages. If there is a recurrence of the<unk> , surgery is again the most notable treatment. Radiotherapy There is not much evidence supporting the claim that radiotherapy is a beneficial and effective means of treatment. Typically, radiotherapy is used postoperatively in respect to whether or not a partial or complete excision of the tumor has been accomplished. The histopathological features of<unk> C, neuronal differentiation, low mitotic activity, absence of vascular endothelial proliferation, and tumor necrosis, suggest that the tumor may be resistant to ionizing radiation. However, when radiotherapy is used, whole brain or involved-field treatment is given. This method utilizes a standard fractionation schedule and a total tumor dose of 50-55 Gy. Gamma knife surgery is a form of radiotherapy, more specifically radiosurgery that uses beams of gamma rays to deliver a certain dosage of radiation to the tumor. Gamma knife surgery is incredibly effective at treating<unk>  and maintaining tumor control after the procedure when a complete excision has been performed. Some studies have found that the success rate of tumor control is around 90% after the first five years and 80% after the first ten years. Gamma knife surgery is the most recorded form of radiotherapy performed to treat remnants of the<unk> C tumor after surgery. Chemotherapy Chemotherapy is typically limited to patients with recurrent<unk> . The course of chemotherapy used for<unk> C is one of two platinum-based regimes. The two regimes are: * Carboplatin + VP-16 + ifosfamide * cisplatin + VP-16 + cyclophosphamide Because chemotherapy is used in rare cases there is still information to be gathered as to the efficacy of chemotherapy to treat benign<unk> C. Therefore, recommendations must be viewed as limited and preliminary. Outcome and recurrence The majority of patients can be expected to be cured of their disease and become long-term survivors of<unk> . As with any other type of tumor, there is a chance for recurrence. The chance of recurrence is approximately 20%. Some factors that predict tumor recurrence and death due to progressive states of disease are high proliferative indices, early disease recurrence, and disseminated disease with or without the spread of disease through the cerebral spinal fluid. Long-term follow up examinations are essential for the evaluation of the outcomes that each treatment brings about. It is also essential to identify possible recurrence of<unk> . It is recommended that a cranial MRI is performed between every 6–12 months.
Central neurocytoma
Neurothekeoma
Subependymoma
Pilocytic astrocytoma
Ganglioglioma
Glial tumor
Mantleoma
Ependymoma